Abstract
Purpose: :
To compare short-term effect of intravitreal triamcinolone acetonide (IVTA) with intravitreal bevacizumab (IVB) injection for diabetic macular edema.
Methods: :
This retrospective, comparative case study included 58 eyes of 35 consecutive patients with diabetic macular edema. IVTA 4 mg or IVB 1.25 mg injection were performed under local anesthesia. Effect of intravitreal injection for diabetic macular edema was evaluated by best-corrected visual acuity (BCVA), macular thickness by OCT and intraocular pressure (IOP) by applanation tonometer. Patients underwent eye examinations, including intraocular pressure, BCVA, macular thickness measurement by OCT at pre-injection, including 2, 4, and 8 weeks post-injections.
Results: :
Mean age ± SD was 58 ± 11.9 years. BCVA (Log MAR) ± SD at pre-injection, including 2, 4, and 8 weeks post-injection were 0.67 ± 0.40, 0.56 ± 0.35, 0.55 ± 0.33, and 0.43 ± 0.31 in IVTA group, 0.51 ± 0.31, 0.43 ± 0.32, 0.42 ± 0.26, and 0.43 ± 0.27 in IVB group, respectively. Macular thickness(µm) ± SD at pre-injection, including 2, 4, and 8 weeks post-injection were 400.4 ± 94.9, 332.8 ± 47.4, 287.5 ± 49.1, and 282.5 ± 49.6 in IVTA group, 372.6 ± 99.5, 360.9 ± 50.3, 368.2 ± 88.6, and 323.2 ± 72.4 7 in IVB group, respectively.
Conclusions: :
IVTA led to more favorable improvement of BCVA than bevacizumab. The effects of IVTA for BCVA and macular thickness were consistent throughout the follow up periods. IVB decreased macular thickness, but the effect of IVB for macular thickness was not significant and short compared to IVTA.
Keywords: diabetic retinopathy • edema • clinical (human) or epidemiologic studies: outcomes/complications